Sabancı University Nanotechnology Research and Application Center (SUNUM) and Nobel İlaç have signed an important cooperation protocol within the framework of industry-university collaboration. Held in SUNUM building, the signing ceremony was attended by SUNUM Director Prof. Fazilet Vardar Sukan and Nobel İlaç Board Member Numan Balki.
Prof. Fazilet Vardar Sukan said the following: “Through the collaboration of these two important institutions, we aim to obtain effective results in the short and medium term in the field of medicine and biotechnology. Considerable contributions will be made to medicine development and commercialization in Turkey thanks to Nobel İlaç’s competencies in the field of biopharmaceuticals, and SUNUM’s competencies in nanotechnology and infrastructure.”
The aim of this cooperation between Nobel İlaç, which is involved in research, development, production, marketing and distribution of pharmaceutical products, and SUNUM, which carries out innovative work in nanotechnology, is to deliver effective results in the field of medicine and biotechnology in the short and medium term.
Thanks to the cooperation, it is planned to make the most of the opportunities offered by “anti-CD 147 inhibitors”-based research program developed by SUNUM for coronaviruses, various cancers and other diseases, and to start research activities for development of registered host cells in the process of manufacturing of biotechnological medicines. The scope of the cooperation also covers initiation of research activities for development of registered environment and buffer solution for industrial cell lines by Nobel İlaç, and support for development of new solutions for different diseases through potential discoveries.